Gabriel Holschneider is an attorney, an entrepreneur, and the founder and president of Rainmaker Group. As a dedicated philanthropist, Gabriel Holschneider supports a number of charitable organizations, including Boston Children’s Hospital.
Researchers at Boston Children’s Hospital are hoping to commence clinical trials on a treatment that uses a patient’s blood cells to treat type 1 diabetes. The same procedure has proven to be successful for treating mice with type 1 diabetes, in that all the animals studied were cured for a short time and one-third were cured for life.
This new treatment has the potential to cure type 1 diabetes by changing the way the immune system functions. Similar studies have attempted to use immunotherapy to cure type 1 diabetes by using a patient’s blood cells to stimulate the immune system.
Researchers at Boston Children’s Hospital are currently working with scientists from the San Diego-based company Fate Therapeutics to design a pill that will modulate stem cells in the blood to treat type 1 diabetes. They have even had a meeting with the U.S. Food and Drug Administration in hopes of commencing a human clinical trial.
